The abstract is read at the publisher; the summary is JClub's.
In the US HIV care and prevention system, only 69% of diagnosed people with HIV are virally suppressed despite >$29 billion in annual treatment spending, linked in part to poverty.
- Why it matters: The gap between high spending and incomplete viral suppression suggests that cost-related prescribing and access barriers may be undermining population-level outcomes.
- What they did: The proposal is to shift prescribing toward lower cost HIV medications, manage medication use for PrEP as higher cost use rises, and reserve long-acting ARVs for people who cannot achieve suppression on oral drugs.
- The result: Redirecting savings from medication utilization management to expand access and socioeconomic support could decrease costs and improve health outcomes while aligning spending with patient preferences.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.